RNAi screen analysis of viral host genes
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
---|---|---|---|---|---|---|
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
23704328 | Primary tooth development (number of teeth) | ADK | 132 | rs7924176 | 8.00E-16 | HIV-1 |
21833088 | Multiple sclerosis | AGAP2 | 116986 | rs12368653 | 2.00E-09 | HIV-1 |
23362303 | Palmitic acid (16:0) plasma levels | ALG14 | 199857 | rs2391388 | 3.00E-11 | HIV-1 |
23362303 | Stearic acid (18:0) plasma levels | ALG14 | 199857 | rs6675668 | 2.00E-18 | HIV-1 |
21833088 | Multiple sclerosis | ALPK2 | 115701 | rs12456021 | 4.00E-06 | HIV-1 |
19043545 | Metabolite levels | ANKRD30A | 91074 | rs1148259 | 3.00E-09 | HIV-1 |
23934736 | Metabolite levels (Pyroglutamine) | ANKRD6 | 22881 | rs6939321 | 4.00E-06 | HIV-1 |
21810271 | vWF and FVIII levels | ANKRD6 | 22881 | rs6454764 | 5.00E-06 | HIV-1 |
21685187 | Chronic obstructive pulmonary disease | ANXA5 | 308 | rs55645543 | 5.00E-07 | HIV-1 |
20205591 | HIV-1 control | AOAH | 313 | rs6948404 | 3.00E-06 | HIV-1 |
21658281 | Sudden cardiac arrest | AP1G2 | 8906 | rs2281680 | 6.00E-08 | HIV-1 |
23643386 | Weight loss (gastric bypass surgery) | AQP11 | 282679 | rs7129556 | 4.00E-06 | HIV-1 |
21533175 | Dehydroepiandrosterone sulphate levels | ARPC1A | 10552 | rs740160 | 2.00E-16 | HIV-1 |
24097068 | HDL cholesterol | ATG7 | 10533 | rs2606736 | 5.00E-08 | HIV-1 |
21983787 | Melanoma | ATM | 472 | rs1801516 | 3.00E-09 | HIV-1 |
23263486 | Urate levels | ATXN2 | 6311 | rs653178 | 7.00E-12 | HIV-1 |
21060863 | Retinal vascular caliber | ATXN2 | 6311 | rs10774625 | 2.00E-13 | HIV-1 |
21738491 | Sudden cardiac arrest | BAZ2B | 29994 | rs4665058 | 2.00E-10 | HIV-1 |
23406172 | Sickle cell anemia (haemolysis) | BCL11A | 53335 | rs766432 | 9.00E-07 | HIV-1 |
22012869 | Attention deficit hyperactivity disorder | BCL11A | 53335 | rs2556378 | 7.00E-06 | HIV-1 |
18245381 | Fetal hemoglobin levels | BCL11A | 53335 | rs11886868 | 7.00E-35 | HIV-1 |
17767159 | F-cell distribution | BCL11A | 53335 | rs1427407 | 6.00E-31 | HIV-1 |
24025145 | Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) | BCL9 | 607 | rs594206 | 6.00E-07 | HIV-1 |
23382809 | Schizophrenia (negative symptoms) | BCL9 | 607 | rs583583 | 6.00E-07 | HIV-1 |
22542470 | Immune response to smallpox vaccine (IL-6) | BCR | 613 | rs9608102 | 8.00E-06 | HIV-1 |
18391951 | Height | BCR | 613 | rs5751614 | 6.00E-06 | HIV-1 |
22610502 | Immune response to smallpox vaccine (IL-6) | BLK | 640 | rs2255327 | 3.00E-07 | HIV-1 |
21452313 | Rheumatoid arthritis | BLK | 640 | rs1600249 | 5.00E-06 | HIV-1 |
19165918 | Systemic lupus erythematosus | BLK | 640 | rs2618476 | 2.00E-08 | HIV-1 |
23535033 | Alzheimer's disease (cognitive decline) | BZW2 | 28969 | rs58370486 | 6.00E-11 | HIV-1 |
20212171 | C4b binding protein levels | C4BPB | 725 | rs3813948 | 4.00E-10 | HIV-1 |
19165232 | Panic disorder | CALCOCO1 | 57658 | rs941184 | 3.00E-07 | HIV-1 |
23568457 | Anorexia nervosa | CAMK1D | 57118 | rs75263140 | 6.00E-06 | HIV-1 |
23459443 | QT interval (interaction) | CAMK1D | 57118 | rs10906189 | 6.00E-06 | HIV-1 |
23251661 | Obesity-related traits | CAMK1D | 57118 | rs10906142 | 4.00E-06 | HIV-1 |
23251661 | Obesity-related traits | CAMK1D | 57118 | rs4750211 | 6.00E-07 | HIV-1 |
21123754 | Alzheimer's disease biomarkers | CCDC134 | 79879 | rs7364180 | 1.00E-06 | HIV-1 |
19734545 | Cognitive performance | CCDC64 | 92558 | rs11064994 | 6.00E-06 | HIV-1 |
23263863 | Mean corpuscular volume | CCND3 | 896 | rs3218097 | 9.00E-08 | HIV-1 |
21102463 | Crohn's disease | CLN3 | 1201 | rs151181 | 2.00E-11 | HIV-1 |
18957941 | Personality dimensions | CLOCK | 9575 | rs6832769 | 2.00E-06 | HIV-1 |
24162737 | Alzheimer's disease (late onset) | CLU | 1191 | rs9331896 | 3.00E-25 | HIV-1 |
21460841 | Alzheimer's disease (late onset) | CLU | 1191 | rs1532278 | 8.00E-08 | HIV-1 |
19734902 | Alzheimer's disease | CLU | 1191 | rs11136000 | 9.00E-10 | HIV-1 |
21483023 | Response to platinum-based chemotherapy in non-small-cell lung cancer | CMKLR1 | 1240 | rs1878022 | 5.00E-07 | HIV-1 |
22726844 | QT interval | CNOT1 | 23019 | rs37060 | 1.00E-07 | HIV-1 |
19305408 | QT interval | CNOT1 | 23019 | rs37062 | 3.00E-25 | HIV-1 |
23291589 | Corneal structure | COL5A1 | 1289 | rs7044529 | 5.00E-12 | HIV-1 |
20834067 | Longevity | COL5A1 | 1289 | rs7874142 | 1.00E-06 | HIV-1 |
23967269 | IgE levels in asthmatics | CRIM1 | 51232 | rs848512 | 1.00E-06 | HIV-1 |
21076409 | Ventricular conduction | CRIM1 | 51232 | rs7562790 | 8.00E-09 | HIV-1 |
23128233 | Inflammatory bowel disease | CRTC3 | 64784 | rs7495132 | 9.00E-11 | HIV-1 |
21130836 | Information processing speed | CRTC3 | 64784 | rs12915189 | 3.00E-06 | HIV-1 |
23535033 | Alzheimer's disease (cognitive decline) | CYCS | 54205 | rs1861525 | 2.00E-07 | HIV-1 |
23266556 | Colorectal cancer | DCBLD1 | 285761 | rs2057314 | 3.00E-06 | HIV-1 |
23563607 | Height | DCBLD1 | 285761 | rs9285425 | 2.00E-08 | HIV-1 |
22566634 | Economic and political preferences | DCBLD1 | 285761 | rs210648 | 2.00E-06 | HIV-1 |
23449627 | Pubertal anthropometrics | DDX55 | 57696 | rs786425 | 3.00E-06 | HIV-1 |
23251661 | Obesity-related traits | DDX60L | 91351 | rs1963569 | 8.00E-06 | HIV-1 |
22449649 | Intelligence | DEPDC5 | 9681 | rs5994434 | 5.00E-07 | HIV-1 |
21725309 | Chronic Hepatitis C infection | DEPDC5 | 9681 | rs1012068 | 1.00E-13 | HIV-1 |
23049088 | Myopia (pathological) | DHX15 | 1665 | rs6841898 | 3.00E-26 | HIV-1 |
23144319 | Non-small cell lung cancer | DLST | 1743 | rs732765 | 7.00E-06 | HIV-1 |
23535033 | Alzheimer's disease (cognitive decline) | DMXL1 | 1657 | rs116348108 | 9.00E-07 | HIV-1 |
21347282 | Coronary heart disease | DNM2 | 1785 | rs11671653 | 9.00E-07 | HIV-1 |
20548944 | Osteoporosis | DOK6 | 220164 | rs17184557 | 9.00E-07 | HIV-1 |
22504421 | Hippocampal volume | DPP4 | 1803 | rs6741949 | 3.00E-07 | HIV-1 |
23251661 | Obesity-related traits | DPYSL5 | 56896 | rs11887277 | 5.00E-06 | HIV-1 |
22581228 | Fasting glucose-related traits (interaction with BMI) | DPYSL5 | 56896 | rs1371614 | 2.00E-12 | HIV-1 |
22286173 | Intracranial aneurysm | EDNRA | 1909 | rs6842241 | 1.00E-08 | HIV-1 |
21531791 | Glioma | EGFR | 1956 | rs11979158 | 7.00E-08 | HIV-1 |
21131975 | Renal cell carcinoma | EPAS1 | 2034 | rs7579899 | 2.00E-09 | HIV-1 |
18464913 | Protein quantitative trait loci | EPS8 | 2059 | rs17415853 | 7.00E-07 | HIV-1 |
23770605 | Chronic lymphocytic leukemia | FAS | 355 | rs4406737 | 1.00E-14 | HIV-1 |
20694011 | Immunoglobulin A | FAS | 355 | rs2234978 | 6.00E-06 | HIV-1 |
23128233 | Inflammatory bowel disease | FEN1 | 2237 | rs4246215 | 2.00E-15 | HIV-1 |
23648065 | Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) | FGD6 | 55785 | rs12310399 | 2.00E-07 | HIV-1 |
23251661 | Obesity-related traits | GCH1 | 2643 | rs3783637 | 1.00E-06 | HIV-1 |
23575436 | Glycemic traits | GCK | 2645 | rs1799884 | 5.00E-18 | HIV-1 |
19096518 | Glycated hemoglobin levels | GCK | 2645 | rs730497 | 6.00E-12 | HIV-1 |
21909115 | Systolic blood pressure | GOSR2 | 9570 | rs17608766 | 1.00E-10 | HIV-1 |
22139419 | Mean platelet volume | GRTP1 | 79774 | rs7317038 | 8.00E-12 | HIV-1 |
23817569 | Self-reported allergy | GSDMB | 55876 | rs9303280 | 9.00E-09 | HIV-1 |
20228799 | Ulcerative colitis | GSDMB | 55876 | rs2305480 | 3.00E-08 | HIV-1 |
19430480 | Type 1 diabetes | GSDMB | 55876 | rs2290400 | 6.00E-13 | HIV-1 |
17611496 | Asthma | GSDMB | 55876 | rs7216389 | 9.00E-11 | HIV-1 |
24097068 | HDL cholesterol | GSK3B | 2932 | rs6805251 | 1.00E-08 | HIV-1 |
23180869 | Pancreatic cancer | GTF2H1 | 2965 | rs9783347 | 9.00E-06 | HIV-1 |
21835309 | Iris characteristics | HERC1 | 8925 | rs11630290 | 1.00E-06 | HIV-1 |
24024966 | Periodontitis (CDC/AAP) | HLA-DOA | 3111 | rs3128935 | 9.00E-06 | HIV-1 |
22139419 | Platelet counts | HLA-DOA | 3111 | rs399604 | 1.00E-10 | HIV-1 |
22959728 | Amyotrophic lateral sclerosis (age of onset) | IFRD1 | 3475 | rs6956741 | 2.00E-06 | HIV-1 |
20400778 | Mortality among heart failure patients | IFRD1 | 3475 | rs17159640 | 9.00E-06 | HIV-1 |
22412388 | Crohn's disease | IL23R | 149233 | rs11209026 | 1.00E-18 | HIV-1 |
19122664 | Ulcerative colitis | IL26 | 55801 | rs2870946 | 5.00E-07 | HIV-1 |
23128233 | Inflammatory bowel disease | IL2RA | 3559 | rs12722515 | 4.00E-10 | HIV-1 |
20410501 | Vitiligo | IL2RA | 3559 | rs706779 | 3.00E-09 | HIV-1 |
23362303 | Oleic acid (18:1n-9) plasma levels | IL5RA | 3568 | rs334809 | 1.00E-06 | HIV-1 |
22542470 | Immune response to smallpox vaccine (IL-6) | IL5RA | 3568 | rs3804795 | 1.00E-06 | HIV-1 |
22365631 | Temperament (bipolar disorder) | INTS7 | 25896 | rs17018311 | 2.00E-08 | HIV-1 |
23314186 | Monocyte count | IRF8 | 3394 | rs424971 | 3.00E-16 | HIV-1 |
21131588 | Chronic lymphocytic leukemia | IRF8 | 3394 | rs391525 | 3.00E-09 | HIV-1 |
23266558 | Crohn's disease | JAK2 | 3717 | rs2274471 | 5.00E-06 | HIV-1 |
19287384 | Myeloproliferative neoplasms | JAK2 | 3717 | rs10974944 | 4.00E-20 | HIV-1 |
19056611 | Type 2 diabetes | KCNJ11 | 3767 | rs5219 | 5.00E-07 | HIV-1 |
18372903 | Type 2 diabetes | KCNJ11 | 3767 | rs5215 | 4.00E-07 | HIV-1 |
20676096 | Hepatocellular carcinoma | KIF1B | 23095 | rs17401966 | 2.00E-18 | HIV-1 |
22197932 | Atopic dermatitis | KIF3A | 11127 | rs2897442 | 4.00E-08 | HIV-1 |
22952603 | Response to amphetamines | KLHL1 | 57626 | rs2325244 | 8.00E-07 | HIV-1 |
22085899 | Bilirubin levels | KLHL1 | 57626 | rs11843309 | 7.00E-06 | HIV-1 |
19734545 | Cognitive performance | KLHL1 | 57626 | rs7984606 | 8.00E-06 | HIV-1 |
22745009 | Hippocampal atrophy | LHFP | 10186 | rs9315702 | 2.00E-08 | HIV-1 |
23776197 | Paclitaxel-induced neuropathy | LIMK2 | 3985 | rs4141404 | 3.00E-06 | HIV-1 |
21150874 | Type 2 diabetes nephropathy | LIMK2 | 3985 | rs2106294 | 4.00E-06 | HIV-1 |
23726366 | HDL cholesterol | LPL | 4023 | rs326 | 1.00E-08 | HIV-1 |
22399527 | Metabolic syndrome | LPL | 4023 | rs268 | 2.00E-12 | HIV-1 |
22171074 | Triglycerides | LPL | 4023 | rs328 | 1.00E-09 | HIV-1 |
21386085 | HDL Cholesterol - Triglycerides (HDLC-TG) | LPL | 4023 | rs13702 | 1.00E-16 | HIV-1 |
21386085 | Metabolic syndrome | LPL | 4023 | rs295 | 2.00E-09 | HIV-1 |
21386085 | Metabolic syndrome (bivariate traits) | LPL | 4023 | rs301 | 3.00E-11 | HIV-1 |
21386085 | Triglycerides-Blood Pressure (TG-BP) | LPL | 4023 | rs15285 | 1.00E-10 | HIV-1 |
20864672 | HDL cholesterol | LPL | 4023 | rs325 | 8.00E-26 | HIV-1 |
19936222 | Lipid metabolism phenotypes | LPL | 4023 | rs331 | 1.00E-17 | HIV-1 |
19936222 | Lipid metabolism phenotypes | LPL | 4023 | rs1059611 | 2.00E-17 | HIV-1 |
21833088 | Multiple sclerosis | MANBA | 4126 | rs228614 | 1.00E-07 | HIV-1 |
21107309 | Reasoning | MAP3K9 | 4293 | rs17108533 | 1.00E-06 | HIV-1 |
21909110 | Blood pressure | MAP4 | 4134 | rs319690 | 3.00E-08 | HIV-1 |
23251661 | Obesity-related traits | MATK | 4145 | rs12104221 | 3.00E-08 | HIV-1 |
23349225 | Osteoporosis | MECOM | 2122 | rs784288 | 4.00E-08 | HIV-1 |
23284291 | Pulmonary function (interaction) | MECOM | 2122 | rs1344555 | 4.00E-06 | HIV-1 |
22797727 | Renal function-related traits (BUN) | MECOM | 2122 | rs16853722 | 3.00E-14 | HIV-1 |
21909115 | Diastolic blood pressure | MECOM | 2122 | rs419076 | 2.00E-12 | HIV-1 |
19197348 | Quantitative traits | MGAT1 | 4245 | rs655601 | 5.00E-06 | HIV-1 |
23509613 | Presence of antiphospholipid antibodies | MICAL3 | 57553 | rs1978968 | 2.00E-06 | HIV-1 |
22001757 | Liver enzyme levels (gamma-glutamyl transferase) | MICAL3 | 57553 | rs1076540 | 1.00E-16 | HIV-1 |
22001756 | Dengue shock syndrome | MICB | 4277 | rs3132468 | 4.00E-11 | HIV-1 |
21946350 | Pulmonary function | MICB | 4277 | rs2855812 | 2.00E-07 | HIV-1 |
22881374 | Alzheimer's disease (late onset) | MPZL1 | 9019 | rs4145462 | 1.00E-06 | HIV-1 |
23989986 | Osteoarthritis (hip) | NACA2 | 342538 | rs17610181 | 8.00E-06 | HIV-1 |
23958962 | Cocaine dependence | NCOR2 | 9612 | rs150954431 | 5.00E-07 | HIV-1 |
23648065 | Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) | NCOR2 | 9612 | rs12582168 | 9.00E-06 | HIV-1 |
19734545 | Cognitive performance | NCOR2 | 9612 | rs12423712 | 7.00E-06 | HIV-1 |
23128233 | Inflammatory bowel disease | NDFIP1 | 80762 | rs6863411 | 4.00E-14 | HIV-1 |
21833088 | Multiple sclerosis | NDFIP1 | 80762 | rs1062158 | 2.00E-06 | HIV-1 |
23910658 | Odorant perception (isobutyraldehyde) | NDUFA10 | 4705 | rs13424612 | 6.00E-10 | HIV-1 |
23471985 | Brain connectivity | NEDD4 | 4734 | rs17819300 | 1.00E-10 | HIV-1 |
20711176 | Keloid | NEDD4 | 4734 | rs8032158 | 6.00E-13 | HIV-1 |
23128233 | Ulcerative colitis | NFKB1 | 4790 | rs3774959 | 4.00E-12 | HIV-1 |
22479419 | Schizophrenia (treatment refractory) | NFKB1 | 4790 | rs230529 | 2.00E-07 | HIV-1 |
23251661 | Obesity-related traits | NIPSNAP3B | 55335 | rs2472476 | 3.00E-06 | HIV-1 |
20935629 | Waist-hip ratio | NISCH | 11188 | rs6784615 | 4.00E-10 | HIV-1 |
23297363 | Tetralogy of Fallot | NRP1 | 8829 | rs2228638 | 2.00E-07 | HIV-1 |
22589738 | Visceral fat | NSUN2 | 54888 | rs6876835 | 3.00E-06 | HIV-1 |
19451621 | Amyotrophic lateral sclerosis | NT5C1A | 84618 | rs873917 | 8.00E-06 | HIV-1 |
23319801 | Breast cancer (prognosis) | NTN1 | 9423 | rs3785982 | 8.00E-06 | HIV-1 |
23921680 | Allergic dermatitis (nickel) | NTN4 | 59277 | rs2367563 | 4.00E-06 | HIV-1 |
23251661 | Obesity-related traits | NUP153 | 9972 | rs2274136 | 3.00E-06 | HIV-1 |
18391951 | Height | NUP153 | 9972 | rs12199222 | 7.00E-07 | HIV-1 |
23934736 | Metabolite levels (Dihydroxy docosatrienoic acid) | NUP98 | 4928 | rs685782 | 7.00E-06 | HIV-1 |
21943158 | Cardiovascular disease risk factors | OASL | 8638 | rs3213545 | 4.00E-15 | HIV-1 |
20581827 | Type 2 diabetes | OASL | 8638 | rs7957197 | 2.00E-08 | HIV-1 |
22747683 | Breast size | OSBPL6 | 114880 | rs34479159 | 6.00E-06 | HIV-1 |
20228798 | Ulcerative colitis | OTUD3 | 23252 | rs4654925 | 9.00E-22 | HIV-1 |
19060910 | Metabolic traits | PANK1 | 53354 | rs11185790 | 3.00E-07 | HIV-1 |
21658281 | Sudden cardiac arrest | PARP4 | 143 | rs9581094 | 7.00E-07 | HIV-1 |
20400778 | Mortality among heart failure patients | PARVA | 55742 | rs7120489 | 7.00E-06 | HIV-1 |
23535033 | Alzheimer's disease (cognitive decline) | PARVB | 29780 | rs75617873 | 5.00E-07 | HIV-1 |
22719876 | Nonalcoholic fatty liver disease | PARVB | 29780 | rs2073080 | 8.00E-07 | HIV-1 |
20881960 | Height | PCCB | 5096 | rs9844666 | 4.00E-09 | HIV-1 |
19136949 | Alzheimer's disease | PCDH11X | 27328 | rs2573905 | 2.00E-07 | HIV-1 |
24068947 | Relative hand skill in reading disability | PCSK6 | 5046 | rs7182874 | 9.00E-09 | HIV-1 |
21051773 | Handedness in dyslexia | PCSK6 | 5046 | rs11855415 | 2.00E-08 | HIV-1 |
23921680 | Allergic dermatitis (nickel) | PELI1 | 57162 | rs6733160 | 7.00E-06 | HIV-1 |
21221998 | Kawasaki disease | PELI1 | 57162 | rs7604693 | 2.00E-06 | HIV-1 |
19430480 | Type 1 diabetes | PGM1 | 5236 | rs2269241 | 4.00E-07 | HIV-1 |
18951430 | Attention deficit hyperactivity disorder and conduct disorder | PKD1L2 | 114780 | rs4889240 | 7.00E-06 | HIV-1 |
18846501 | Conduct disorder (interaction) | PPM1K | 152926 | rs893971 | 7.00E-06 | HIV-1 |
23563607 | Height | PPP2R2A | 5520 | rs1594829 | 4.00E-08 | HIV-1 |
21659360 | Response to antineoplastic agents | PPP2R5E | 5529 | rs11158493 | 9.00E-07 | HIV-1 |
23666240 | Testicular germ cell tumor | PRDM14 | 63978 | rs7010162 | 5.00E-08 | HIV-1 |
22037551 | Gastric cancer | PRKAA1 | 5562 | rs13361707 | 8.00E-29 | HIV-1 |
23738518 | Reading and spelling | PRKCH | 5583 | rs17098356 | 6.00E-06 | HIV-1 |
23738518 | Word reading | PRKCH | 5583 | rs11158345 | 3.00E-06 | HIV-1 |
23563609 | Obesity (early onset extreme) | PRKCH | 5583 | rs1957894 | 3.00E-10 | HIV-1 |
22446963 | Rheumatoid arthritis | PRKCH | 5583 | rs1957895 | 4.00E-07 | HIV-1 |
23563607 | Height | PSMC3 | 5702 | rs10838708 | 2.00E-09 | HIV-1 |
23022100 | Serum albumin level | PSMC3 | 5702 | rs2293579 | 8.00E-08 | HIV-1 |
20139978 | White blood cell count | PSMD3 | 5709 | rs4065321 | 3.00E-14 | HIV-1 |
23563607 | Height | PTPRJ | 5795 | rs10838798 | 7.00E-12 | HIV-1 |
22076464 | Acute lymphoblastic leukemia (childhood) | PTPRJ | 5795 | rs3942852 | 1.00E-06 | HIV-1 |
23251661 | Obesity-related traits | PTPRN2 | 5799 | rs7786808 | 8.00E-06 | HIV-1 |
23049088 | Myopia (pathological) | PTPRN2 | 5799 | rs10274279 | 4.00E-11 | HIV-1 |
22952603 | Response to amphetamines | PTPRN2 | 5799 | rs4909189 | 3.00E-06 | HIV-1 |
21057379 | Bipolar disorder and schizophrenia | PTPRN2 | 5799 | rs6459804 | 8.00E-06 | HIV-1 |
24132900 | Psychosis (atypical) | PVT1 | 5820 | rs16902460 | 3.00E-06 | HIV-1 |
21037568 | Hodgkin's lymphoma | PVT1 | 5820 | rs2608053 | 1.00E-07 | HIV-1 |
17395743 | End-stage renal disease | PVT1 | 5820 | rs2648875 | 2.00E-06 | HIV-1 |
22589738 | Visceral fat | RANBP17 | 64901 | rs2278255 | 5.00E-06 | HIV-1 |
24097068 | HDL cholesterol | RBM5 | 10181 | rs2013208 | 9.00E-12 | HIV-1 |
24026423 | Platelet counts | RCL1 | 10171 | rs423955 | 1.00E-09 | HIV-1 |
23263863 | Mean corpuscular hemoglobin | RCL1 | 10171 | rs10815094 | 5.00E-06 | HIV-1 |
23263863 | Mean corpuscular volume | RCL1 | 10171 | rs2236496 | 2.00E-07 | HIV-1 |
23263863 | Platelet counts | RCL1 | 10171 | rs457287 | 1.00E-06 | HIV-1 |
22139419 | Platelet counts | RCL1 | 10171 | rs13300663 | 1.00E-29 | HIV-1 |
19862010 | Mean corpuscular hemoglobin | RCL1 | 10171 | rs10758658 | 2.00E-14 | HIV-1 |
18839057 | Attention deficit hyperactivity disorder | REEP5 | 7905 | rs469727 | 8.00E-06 | HIV-1 |
20018961 | Leprosy | RIPK2 | 8767 | rs42490 | 1.00E-16 | HIV-1 |
23412934 | Multiple sclerosis | RNASEL | 6041 | rs533259 | 6.00E-09 | HIV-1 |
23028342 | Type 1 diabetes nephropathy | RNF10 | 9921 | rs614226 | 2.00E-06 | HIV-1 |
23966867 | Waist-hip ratio | RREB1 | 6239 | rs6931262 | 3.00E-08 | HIV-1 |
22581228 | Fasting glucose-related traits (interaction with BMI) | RREB1 | 6239 | rs2714337 | 3.00E-07 | HIV-1 |
22589738 | Visceral adipose tissue adjusted for BMI | RREB1 | 6239 | rs2842895 | 4.00E-06 | HIV-1 |
21833088 | Multiple sclerosis | RREB1 | 6239 | rs11755724 | 3.00E-06 | HIV-1 |
22719876 | Nonalcoholic fatty liver disease | SAMM50 | 25813 | rs2143571 | 6.00E-07 | HIV-1 |
23180869 | Pancreatic cancer | SBF2 | 81846 | rs10500715 | 2.00E-07 | HIV-1 |
19734545 | Cognitive performance | SEC14L1 | 6397 | rs3744064 | 7.00E-07 | HIV-1 |
21642993 | Esophageal cancer | SEMA5B | 54437 | rs9868873 | 1.00E-07 | HIV-1 |
24026423 | Platelet counts | SH2B3 | 10019 | rs3184504 | 5.00E-11 | HIV-1 |
23728906 | Insomnia | SLC2A13 | 114134 | rs11174478 | 2.00E-06 | HIV-1 |
23728906 | Sleep quality | SLC2A13 | 114134 | rs1005956 | 3.00E-06 | HIV-1 |
22451204 | Parkinson's disease | SLC2A13 | 114134 | rs10877840 | 1.00E-06 | HIV-1 |
23535729 | Breast cancer | SLC4A7 | 9497 | rs4973768 | 2.00E-30 | HIV-1 |
23817569 | Self-reported allergy | SMAD3 | 4088 | rs17228058 | 1.00E-08 | HIV-1 |
23291589 | Corneal structure | SMAD3 | 4088 | rs12913547 | 5.00E-10 | HIV-1 |
23128233 | Inflammatory bowel disease | SMAD3 | 4088 | rs17293632 | 6.00E-16 | HIV-1 |
20860503 | Asthma | SMAD3 | 4088 | rs744910 | 4.00E-09 | HIV-1 |
17634449 | Coronary heart disease | SMAD3 | 4088 | rs17228212 | 2.00E-07 | HIV-1 |
22482804 | Crohn's disease and psoriasis | SOCS1 | 8651 | rs4780355 | 1.00E-13 | HIV-1 |
23251661 | Obesity-related traits | SP110 | 3431 | rs13010639 | 6.00E-06 | HIV-1 |
22685421 | Myopia (pathological) | SPTBN1 | 6711 | rs4557020 | 3.00E-07 | HIV-1 |
19801982 | Bone mineral density (spine) | SPTBN1 | 6711 | rs11898505 | 2.00E-08 | HIV-1 |
21665994 | Alcohol consumption (transferrin glycosylation) | SRPRB | 58477 | rs1534166 | 2.00E-17 | HIV-1 |
22959728 | Amyotrophic lateral sclerosis (age of onset) | ST3GAL3 | 6487 | rs3011225 | 7.00E-08 | HIV-1 |
21782286 | Aging (time to event) | ST3GAL3 | 6487 | rs2367725 | 9.00E-06 | HIV-1 |
24097068 | HDL cholesterol | STAB1 | 23166 | rs13326165 | 9.00E-11 | HIV-1 |
22310353 | Treatment response for severe sepsis | STARD3NL | 83930 | rs4723738 | 6.00E-06 | HIV-1 |
21784300 | Attention deficit hyperactivity disorder | STIP1 | 10963 | rs11607165 | 4.00E-06 | HIV-1 |
23722424 | Educational attainment | STK24 | 8428 | rs3783006 | 8.00E-08 | HIV-1 |
22159054 | Alzheimer's disease | STK24 | 8428 | rs912330 | 4.00E-06 | HIV-1 |
20834067 | Longevity | STK24 | 8428 | rs9517320 | 1.00E-06 | HIV-1 |
23453885 | Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) | STT3A | 3703 | rs548181 | 9.00E-07 | HIV-1 |
23146381 | IgE levels | SUCLG2 | 8801 | rs2363709 | 5.00E-06 | HIV-1 |
22144915 | Corneal astigmatism | SUCLG2 | 8801 | rs6792584 | 5.00E-06 | HIV-1 |
20881960 | Height | SUCLG2 | 8801 | rs17806888 | 2.00E-09 | HIV-1 |
18937294 | Attention deficit hyperactivity disorder (time to onset) | SULF2 | 55959 | rs4810685 | 7.00E-06 | HIV-1 |
23382691 | IgG glycosylation | SUV420H1 | 51111 | rs4930561 | 1.00E-08 | HIV-1 |
24026423 | Mean platelet volume | TAOK1 | 57551 | rs9900280 | 1.00E-10 | HIV-1 |
22139419 | Platelet counts | TAOK1 | 57551 | rs559972 | 3.00E-18 | HIV-1 |
21490949 | Type 2 diabetes | TCERG1L | 256536 | rs10741243 | 5.00E-06 | HIV-1 |
23251661 | Obesity-related traits | TCFL5 | 10732 | rs17854409 | 9.00E-06 | HIV-1 |
20383146 | Chronic kidney disease | TFDP2 | 7029 | rs347685 | 3.00E-11 | HIV-1 |
23251661 | Obesity-related traits | TM9SF2 | 9375 | rs9513627 | 4.00E-06 | HIV-1 |
24025145 | Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) | TMEM132C | 92293 | rs11059635 | 2.00E-07 | HIV-1 |
23456168 | Height | TMEM132C | 92293 | rs10773568 | 3.00E-06 | HIV-1 |
21423239 | Suicide attempts in bipolar disorder | TMEM132C | 92293 | rs7296262 | 1.00E-06 | HIV-1 |
22885689 | Schizophrenia | TMTC1 | 83857 | rs16934812 | 7.00E-06 | HIV-1 |
23053960 | Systemic lupus erythematosus | TNPO3 | 23534 | rs12531711 | 6.00E-13 | HIV-1 |
21750679 | Systemic sclerosis | TNPO3 | 23534 | rs10488631 | 4.00E-07 | HIV-1 |
24097068 | Cholesterol, total | TOM1 | 10043 | rs138777 | 5.00E-08 | HIV-1 |
23936387 | Celiac disease | TPTE | 7179 | rs10439884 | 2.00E-06 | HIV-1 |
19875103 | Response to antipsychotic therapy (extrapyramidal side effects) | TRIM44 | 54765 | rs7928794 | 8.00E-06 | HIV-1 |
23222517 | Red blood cell traits | TRIM58 | 25893 | rs3811444 | 5.00E-10 | HIV-1 |
21102462 | Menarche (age at onset) | TRIM66 | 9866 | rs4929923 | 1.00E-08 | HIV-1 |
23563607 | Obesity | TRIM66 | 9866 | rs11042023 | 1.00E-11 | HIV-1 |
23535732 | Prostate cancer | TRIM8 | 81603 | rs3850699 | 5.00E-10 | HIV-1 |
20463881 | Eye color traits | TTC3 | 7267 | rs1003719 | 2.00E-10 | HIV-1 |
21829393 | Type 1 diabetes autoantibodies | UBASH3A | 53347 | rs3788013 | 1.00E-07 | HIV-1 |
21383967 | Celiac disease and Rheumatoid arthritis | UBASH3A | 53347 | rs11203203 | 1.00E-08 | HIV-1 |
18840781 | Type 1 diabetes | UBASH3A | 53347 | rs9976767 | 2.00E-08 | HIV-1 |
23128233 | Inflammatory bowel disease | UBE2L3 | 7332 | rs2266959 | 1.00E-16 | HIV-1 |
24162738 | Hepatitis B | UBE2L3 | 7332 | rs4821116 | 2.00E-12 | HIV-1 |
24097068 | HDL cholesterol | UBE2L3 | 7332 | rs181362 | 4.00E-18 | HIV-1 |
23273568 | Systemic lupus erythematosus | UBE2L3 | 7332 | rs5754217 | 5.00E-06 | HIV-1 |
20139978 | Mean corpuscular volume | UBE2L3 | 7332 | rs4821112 | 1.00E-08 | HIV-1 |
19838193 | Systemic lupus erythematosus | UBE2L3 | 7332 | rs131654 | 1.00E-16 | HIV-1 |
21378990 | Coronary heart disease | UBE2Z | 65264 | rs46522 | 2.00E-08 | HIV-1 |
23666239 | Testicular germ cell tumor | UCK2 | 7371 | rs4657482 | 6.00E-06 | HIV-1 |
23666240 | Testicular germ cell tumor | UCK2 | 7371 | rs3790672 | 2.00E-08 | HIV-1 |
23251661 | Obesity-related traits | UMODL1 | 89766 | rs220299 | 4.00E-07 | HIV-1 |
23535732 | Prostate cancer | VPS53 | 55275 | rs684232 | 5.00E-15 | HIV-1 |
23534349 | PR interval | VWC2L | 402117 | rs7604827 | 5.00E-06 | HIV-1 |
23267103 | Coagulation factor levels | VWF | 7450 | rs1063856 | 5.00E-16 | HIV-1 |
20383146 | Chronic kidney disease | WDR37 | 22884 | rs10794720 | 1.00E-08 | HIV-1 |
22960999 | Esophageal cancer (squamous cell) | XBP1 | 7494 | rs2239815 | 4.00E-15 | HIV-1 |
22610502 | Immune reponse to smallpox (secreted IL-1beta) | XKR4 | 114786 | rs12542677 | 2.00E-07 | HIV-1 |
23535732 | Prostate cancer | ZGPAT | 84619 | rs6062509 | 4.00E-16 | HIV-1 |
23128233 | Inflammatory bowel disease | ZGPAT | 84619 | rs6062504 | 1.00E-23 | HIV-1 |
18758464 | Inflammatory bowel disease | ZGPAT | 84619 | rs2315008 | 9.00E-15 | HIV-1 |
21116278 | MRI atrophy measures | ZNF292 | 23036 | rs1925690 | 3.00E-08 | HIV-1 |
23128233 | Inflammatory bowel disease | ZNF831 | 128611 | rs259964 | 1.00E-12 | HIV-1 |
19875103 | Response to antipsychotic therapy (extrapyramidal side effects) | ZNF831 | 128611 | rs12625057 | 7.00E-06 | HIV-1 |